The company believes that the new OTC analgesic could provide an alternative to current OTC pain relievers.
According to an August 2010 report published by the US Census Bureau the manufacturers’ revenue from internal non-narcotic analgesics, antipyretics, anti-arthritics, and anti-inflammatories, including salicylates and acetaminophen, totaled $2.4bn in 2009, in the US.
Divine Skin develops biotechnology for topical, nutritional and pharmaceutical therapies and markets through online and specialty retailers, cosmetics wholesalers, salons, and medical offices.